Barcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.
Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.
London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.
Parisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.
Elnur Amikishiyev-stock.adobe.comA restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor consortium has acquired the company’s pharma technology business and relaunched it as Lucera GmbH. Dr Friedrich von Bohlen remains at the helm, while Dr Stephan Brock, the mind behind the Dataome data engine, also stays on board as CTO.
Oxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour types, presenting Phase 1b data from the EMITT-1 trial at the 2026 ASCO Annual Meeting.
Immatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation program.
Swiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to meet their primary endpoint.
French pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, giving the Paris-based company a late-stage entry into Becker and Duchenne muscular dystrophy.
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.comT-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and LNP company Pantherna Therapeutics. Financial details of the transaction were not disclosed. Pantherna is to continue operating in Hennigsdorf as a wholly owned subsidiary.